ClinicalTrials.gg
RecruitingNCT02781922APOLLONUpdated Oct 19, 2026

Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)

A Phase 3 interventional study of Autologous cardiac stem cells (JRM-001) in Hypoplastic Left Heart Syndrome and Single Ventricle, sponsored by Metcela Inc.. Recruiting at 4 sites in Japan. Open to participants aged 0 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Metcela Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 19, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
0 Years to 6 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of intracoronary injection of JRM-001 after reconstructive surgery in pediatric patients with functional single ventricle

02

Conditions studied

  • Hypoplastic Left Heart Syndrome
  • Single Ventricle

Keywords

  • cardiac stem/progenitor cells
  • autologous cell therapy
  • functional single ventricle
  • congenital heart disease
03

In context

Hypoplastic Left Heart Syndrome

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

This study's planned enrollment of 40 is above the median of 30 across 41 interventional studies indexed under Hypoplastic Left Heart Syndrome.

Browse Hypoplastic Left Heart Syndrome studies →

Lead sponsor

Metcela Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Functional single ventricle patient with heart failure who is scheduled for stage 2 (Glenn) or stage 3 (Fontan) surgery
  • EF(%) by echocardiography ≤ 55%
  • Able to obtain written of participation in the study by a parent of the patient

Exclusion criteria

Exclusion Criteria:

  • Known medical history of cardiogenic shock
  • Lethal, uncontrollable arrhythmia
  • Complication of coronary artery disease
  • Eisenmenger syndrome
  • Complication of brain dysfunction due to circulatory failure
  • Malignant neoplasm
  • Complication of severe neurologic disorder
  • Severe pulmonary embolism or pulmonary hypertension
  • Severe renal failure
  • Multiple organ failure
  • Active infection (including endocarditis)
  • Sepsis
  • Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury)
  • Known history of to anti-infective drugs
  • Inability to complete the protocol treatment and baseline to follow-up examinations
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Autologous cardiac stem cells (JRM-001)

    Genetic: Autologous cardiac stem cells (JRM-001)

  • No intervention
    Usual care

Interventions

  • GeneticAutologous cardiac stem cells (JRM-001)

    3x 10\^5 cells/kg, single treatment

06

What researchers measure

Primary outcomes

  1. Change in ejection fraction (EF(%)) assessed by MRI from baseline

    Time frame: Baseline, 6 and 12 months

Secondary outcomes

  1. Change in EF(%) assessed by echocardiograms from baseline

    Time frame: Screening, Baseline, 3, 6 and 12 months

  2. Change in EF(%) assessed by cardiac catheterization from baseline

    Time frame: Baseline, 6 and 12 months

  3. Change in Ea/Ees assessed by cardiac catheterization from baseline

    Time frame: Baseline, 6 and 12 months

  4. Change in Ventricular Stiffness assessed by cardiac catheterization from baseline

    Time frame: Baseline, 6 and 12 months

  5. Change in heart failure index from baseline

    Time frame: Baseline, 3, 6 and 12 months

  6. Change in Quality of Life (QOL) index from baseline

    Time frame: Baseline, 6 and 12 months

  7. Number of adverse events

    Time frame: Up to 12 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015 Feb 13;116(4):653-64. doi: 10.1161/CIRCRESAHA.116.304671. Epub 2014 Nov 17. PubMed 25403163 ↗
  • Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015 Nov;150(5):1198-1207, 1208.e1-2. doi: 10.1016/j.jtcvs.2015.06.076. Epub 2015 Jul 8. PubMed 26232942 ↗
  • Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, Hirai K, Fukushima Y, Baba K, Goto T, Horio N, Kobayashi J, Kuroko Y, Kotani Y, Arai S, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ Res. 2017 Mar 31;120(7):1162-1173. doi: 10.1161/CIRCRESAHA.116.310253. Epub 2017 Jan 4. PubMed 28052915 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2016
First posted
May 25, 2016
Start
Jun 2016
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Osaka Women's and Children's Hospital · Osaka, Japan
Show 1 removed
  • Saitama Prefectural Children's Medical Center · Saitama, Japan
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • Osaka Women's and Children's Hospital · Osaka, Japan
    Show 1 removed
    • Saitama Prefectural Children's Medical Center · Saitama, Japan
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02781922
Lead sponsor
Metcela Inc.
Responsible party
Sponsor
First posted
May 25, 2016
Start date
Jun 2016
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Metcela Inc. (former Japan Regenerative Medicine Co., Ltd.)
Contact
info@j-rm.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion